This week, the FDA decided in a 10:7 vote to approve Provention Bio’s teplizumab, a drug that could delay the onset of type 1 diabetes for up to two years for high-risk individuals. Recent clinical trial data suggest…
Implications of Stigma in Diabetes
We recently asked members of the dQ&A US Patient Panel about stigma in diabetes…
COVID Fears Kept One in Five People With Diabetes Away From the Doctor During Pandemic
Results released by dQ&A and the…
Breaking Data on COVID-19 Vaccination Rates Among People with Diabetes
While people with diabetes have been prioritized for vaccine eligibility…
Major Pharmacies Failing to Meet the Needs of People With Diabetes, According to National dQ&A® Survey
There is a wide variation in quality…
“A Day You Will Never Forget”
Being diagnosed with diabetes can be a life-changing experience. To better understand the diagnosis experience, we reached out…
Income Related to Worse Outcomes in People with Type 2 Diabetes
Respondents in the lower-income bracket are more likely…
Presentation to Congressional Diabetes Caucus
dQ&A and the ADA presented data to the Congressional Diabetes Caucus on COVID-19’s impact…
dQ&A CGM Series Part 2: The Tidal Wave of CGM
In Part 1 of our exclusive CGM series, we covered the ‘tidal wave’ of CGM in diabetes. In Part 2, we are diving…
COVID-19: Resurgence in Fears for Diabetes Community in the United States
In previous waves, fears were trending downwards…
